# Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

> **NCT00366106** · PHASE2 · TERMINATED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin HCl liposome

## Key facts

- **NCT ID:** NCT00366106
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.
- **Last updated:** 2012-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366106, "Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00366106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*